Navigation Links
Primary Endpoint Achieved in CAVATAK Phase 2 Melanoma Trial
Date:9/18/2013

melanoma patients."

There are now 44 patients enrolled in the study with full enrollment forecast by the end of 2013.

Additional details about the Phase 2 CALM clinical trial can be found in the full ASX release issued by Viralytics:

http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=01444703

Full details of the clinical trial design can be found at the following website:

http://clinicaltrials.gov/show/NCT01227551

About Viralytics Ltd:

Viralytics is developing oncolytic virotherapy treatments for a range of cancers.  Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21).  CVA21 binds to specific "receptor" proteins highly expressed on multiple cancer types including, but not limited to melanoma, prostate, lung, breast and bladder cancers; and multiple myeloma.  Intratumourally administered CAVATAKTM is currently being studied in a Phase 2 clinical trial in the treatment of Late stage Melanoma (the CALM study) at multiple cancer clinics in the US. 

Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. Viralytics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency and will commence the STORM trial at three prominent UK sites later in 2013.

Based in Sydney Australia, Viralytics is listed on the Australian Securities Exchange (ASX: VLA) while its ADRs also trade under VRACY on the US OTCQX International market.
'/>"/>

SOURCE Viralytics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
4. ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
5. TREATMENT OF PRIMARY LIVER CANCER: SARAH STUDY NOW AVAILABLE FOR ALL ELIGIBLE PATIENTS THROUGHOUT FRANCE
6. OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
9. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
10. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
11. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Consumables Market - Global Industry Analysis, Size, Share, ... report to their offering. (Logo: ... consumables are products which are used on patients ... restoration and in treatment of associated gingival tissues. ...
(Date:1/15/2014)... 2014 AARP Foundation today announced it has ... adults suffering from the severe cold weather that has ... are committed to helping those in need; so to ... will match dollar-for-dollar contributions up to $250,000, which could ... will be administered through AARP Foundation. ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate ... stock in an at-the-market registered direct offering, led ... The Company entered into definitive purchase agreements with ... to sell an aggregate of 3,603,603 shares of ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
(Date:4/14/2014)... Ford Hospital reached a medical milestone April 3, ... a novel way to access the heart. , ... United States performing the unique procedure called transcaval ... connecting major blood vessels. , Northern Michigan resident ... procedure on July 3, 2013 when traditional valve ...
(Date:4/14/2014)... shows that moderate to severe obstructive sleep apnea is ... and death. , Results of the 20-year follow-up study ... apnea were four times more likely to die (hazard ... have a stroke (HR = 3.7), three times more ... 2.5 times more likely to develop cancer. Results were ...
(Date:4/14/2014)... DALLAS April 14, 2014 Popular web information ... people to read and doesn,t address the appropriate risks ... Southwestern Medical Center gastroenterologists suggests. , In a review ... patient education materials for colorectal cancer screening were written ... the sites failed to address key risks, as well ...
(Date:4/14/2014)... Ohio A new study identifies a molecule that ... suggests that the molecule could be an important target ... tumor progression. , The study of microRNA-135b (miR-135b) in ... the journal Cancer Cell and was led ... Center Arthur G. James Cancer Hospital and Richard ...
(Date:4/14/2014)... have unearthed still more evidence that antibiotics can ... print in the journal Antimicrobial Agents and ... treatment gained weight and had significant changes in ... by Didier Raoult, of Aix-Marseille University, Marseille, France, ... with doxycycline and hydroxychloroquine for Q fever, and ...
Breaking Medicine News(10 mins):Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Long-term antibiotic treatment for Q fever causes weight gain 2
... was $ 0.28 per share ... ... Oct. 11 Herley Industries,Inc. (Nasdaq: HRLY ) today reported its financial results for ... quarter of 2007 was $3.8 million or $.28,per share, as compared to $713,000 or $.05 ...
... a simple tool that can improve the effectiveness of ... result in dramatic improvements in health and safety. , ... with color images of the medication to be taken ... in a patient,s native language if the patient does ...
... law firm of Kohn, Swift &,Graf, P.C. announces that ... Corporation ("Pall" or the "Company") (NYSE: PLL ).,The ... the Eastern,District of New York, seeks damages for violations ... purchased Pall securities between April,20, 2007 and August 8, ...
... 11, 2007 Cancer researchers have long worked to ... of therapies designed to stop the production of testosterone ... research has now detected that androgen-synthesizing proteins are present ... develop the capacity to produce their own androgens. ...
... protein previously implicated in prostate and breast cancer development ... pancreatic cancer. Researchers at the Kimmel Cancer Center at ... which normally applies the brakes on a cancer-causing ... pancreatic cancer. Though the work is preliminary, the scientists ...
... (Nasdaq: ALXN ), today announced that the Company ... Thursday, October 25, 2007,at 10:00 a.m. Eastern Time (ET), ... the third quarter ended September 30, 2007. Alexion,anticipates releasing ... 25, 2007. To participate in this conference call, ...
Cached Medicine News:Health News:Herley Reports 4th Quarter and Year-End Results 2Health News:Herley Reports 4th Quarter and Year-End Results 3Health News:Herley Reports 4th Quarter and Year-End Results 4Health News:Herley Reports 4th Quarter and Year-End Results 5Health News:Herley Reports 4th Quarter and Year-End Results 6Health News:Herley Reports 4th Quarter and Year-End Results 7Health News:Herley Reports 4th Quarter and Year-End Results 8Health News:Herley Reports 4th Quarter and Year-End Results 9Health News:Herley Reports 4th Quarter and Year-End Results 10Health News:Herley Reports 4th Quarter and Year-End Results 11Health News:Improving doctor-patient communication yields significant health benefits 2Health News:Improving doctor-patient communication yields significant health benefits 3Health News:Improving doctor-patient communication yields significant health benefits 4Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 2Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 3Health News:New research may show why some prostate cancer recurs after treatment 2Health News:New research may show why some prostate cancer recurs after treatment 3Health News:Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer 2
The UltraLite Post Op Brace provides a fixed or range of motion control. The UltraLite Post Op Brace indications include: , Post knee trauma , Peri-operative use , Conservative management of isolated...
... was designed to meet the constant demands ... kit provides all components necessary to fit ... 1002-A4 Aluminum pre-contoured adjustable knee joints , ... 2 Unique adjustable thigh bands , Ortho-wick™ ...
... This lightweight orthosis is designed ... basilar joint while allowing unobstructed motion ... a more custom fit the splint ... and formed using a heat gun. ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: